Q3 2025 · 13F-HR
GILEAD SCIENCES, INC. (GILD)holdings as filed
Filed 2025-11-13 · accession 0001123292-25-000642
$1.79B
Reported value
9
Positions
2025-09-30
Period end
The Brief · GILEAD SCIENCES, INC. (GILD) · Q3 2025
AI · grounded in 13F
GILEAD SCIENCES, INC. (GILD) established a new position in GALAPAGOS NV LKFT valued at $578.7M. The fund also initiated new stakes in ARCELLX INC ACLXGBX for $551.8M and ARCUS BIOSCIENCES INC RCUS for $427.4M. Other new additions include ASSEMBLY BIOSCIENCES INC ASMB, MERUS N V 2GH, and TANGO THERAPEUTICS INC TNGX.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 36315X101 | LKFT | GALAPAGOS NV | $578.7M | 32.3% | 16,707,477 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $551.8M | 30.8% | 6,720,803 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $427.4M | 23.9% | 31,424,760 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $115.3M | 6.44% | 4,505,391 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $42.6M | 2.38% | 452,527 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $40.8M | 2.28% | 4,854,443 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $24.8M | 1.38% | 4,126,119 | Common | SOLE |
| 98422T100 | XLO | XILIO THERAPEUTICS INC | $7.7M | 0.43% | 9,105,451 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $2.4M | 0.13% | 5,319,148 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.